307 related articles for article (PubMed ID: 33272956)
1. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
Fischer-Barnicol B; Oechtering J; Kuhle J; Lorscheider J; Kappos L; Derfuss T
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272956
[No Abstract] [Full Text] [Related]
2. Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference Proceedings.
Anadani N; Hyland M; Cruz RA; Lisak R; Costello K; Major EO; Jassam Y; Meltzer E; Varkey TC; Parsons MS; Goodman AD; Graves JS; Newsome S; Zamvil SS; Frohman EM; Frohman TC
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33411672
[No Abstract] [Full Text] [Related]
3. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
[TBL] [Abstract][Full Text] [Related]
4. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis, a treatable disease .
Doshi A; Chataway J
Clin Med (Lond); 2017 Dec; 17(6):530-536. PubMed ID: 29196354
[TBL] [Abstract][Full Text] [Related]
6. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.
Sinnecker T; Hadisurya J; Schneider-Hohendorf T; Schwab N; Wrede K; Gembruch O; Gold R; Hellwig K; Pilgram-Pastor S; Adams O; Albrecht P; Hartung HP; Aktas O; Kraemer M
BMC Neurol; 2019 Aug; 19(1):190. PubMed ID: 31399069
[TBL] [Abstract][Full Text] [Related]
7. An updated review of teriflunomide's use in multiple sclerosis.
Miller AE
Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
[TBL] [Abstract][Full Text] [Related]
8. Ponesimod (Ponvory) for multiple sclerosis.
Med Lett Drugs Ther; 2021 Aug; 63(1630):123-125. PubMed ID: 34550110
[No Abstract] [Full Text] [Related]
9. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
10. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
[TBL] [Abstract][Full Text] [Related]
14. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P;
Mult Scler; 2014 May; 20(6):705-16. PubMed ID: 24126064
[TBL] [Abstract][Full Text] [Related]
15. ▼Teriflunomide for multiple sclerosis.
Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
[TBL] [Abstract][Full Text] [Related]
16. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
17. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod-associated PML in a patient with prior immunosuppression.
Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
[No Abstract] [Full Text] [Related]
19. Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.
Möhn N; Saker F; Bonda V; Respondek G; Bachmann M; Stoll M; Wattjes MP; Stangel M; Skripuletz T
J Neurol; 2020 Oct; 267(10):2803-2805. PubMed ID: 32494855
[No Abstract] [Full Text] [Related]
20. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Ingwersen J; Aktas O; Hartung HP
Neurotherapeutics; 2016 Jan; 13(1):47-57. PubMed ID: 26701666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
